2025 first_quarter Filing

Federal policy relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; and Federal policy relating to providing incentives to spur domestic manufacturing of generic drugs.

Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to the implementation of a pharmaceutical manufacturer reliability rating system and incentives in the Medicare program for providers to purchase generic drugs from manufacturers with higher reliability ratings; and Federal policy relating to the structure of the Department of Health and Human Services.